CY2017027I1 - Σταθεροποιημενες συνθεσεις πτητικων αλκυλιωτικων παραγοντων και μεθοδοι χρησης αυτων - Google Patents

Σταθεροποιημενες συνθεσεις πτητικων αλκυλιωτικων παραγοντων και μεθοδοι χρησης αυτων

Info

Publication number
CY2017027I1
CY2017027I1 CY2017027C CY2017027C CY2017027I1 CY 2017027 I1 CY2017027 I1 CY 2017027I1 CY 2017027 C CY2017027 C CY 2017027C CY 2017027 C CY2017027 C CY 2017027C CY 2017027 I1 CY2017027 I1 CY 2017027I1
Authority
CY
Cyprus
Prior art keywords
methods
alkylating agents
stabilized compositions
volatile alkylating
volatile
Prior art date
Application number
CY2017027C
Other languages
English (en)
Other versions
CY2017027I2 (el
Original Assignee
Actelion Pharmaceuticals Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36971840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2017027(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd. filed Critical Actelion Pharmaceuticals Ltd.
Publication of CY2017027I1 publication Critical patent/CY2017027I1/el
Publication of CY2017027I2 publication Critical patent/CY2017027I2/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/15—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CY2017027C 2005-03-14 2017-08-10 Σταθεροποιημενες συνθεσεις πτητικων αλκυλιωτικων παραγοντων και μεθοδοι χρησης αυτων CY2017027I2 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US66135605P 2005-03-14 2005-03-14
US75112805P 2005-12-16 2005-12-16
US11/369,305 US7872050B2 (en) 2005-03-14 2006-03-07 Stabilized compositions of volatile alkylating agents and methods of using thereof
PCT/US2006/009060 WO2006099385A2 (en) 2005-03-14 2006-03-14 Stabilized compositions of volatile alkylating agents and methods of using thereof

Publications (2)

Publication Number Publication Date
CY2017027I1 true CY2017027I1 (el) 2018-04-04
CY2017027I2 CY2017027I2 (el) 2018-04-04

Family

ID=36971840

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20121100855T CY1113305T1 (el) 2005-03-14 2012-09-19 Σταθεροποιημενες συνθεσεις πτητικων αλκυλιωτικων παραγοντων και μεθοδοι χρησης αυτων
CY2017027C CY2017027I2 (el) 2005-03-14 2017-08-10 Σταθεροποιημενες συνθεσεις πτητικων αλκυλιωτικων παραγοντων και μεθοδοι χρησης αυτων

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20121100855T CY1113305T1 (el) 2005-03-14 2012-09-19 Σταθεροποιημενες συνθεσεις πτητικων αλκυλιωτικων παραγοντων και μεθοδοι χρησης αυτων

Country Status (19)

Country Link
US (7) US7872050B2 (el)
EP (1) EP1858864B1 (el)
JP (2) JP5236457B2 (el)
KR (1) KR101168252B1 (el)
CN (1) CN101175735B (el)
AU (1) AU2006223076B2 (el)
CA (1) CA2600468C (el)
CY (2) CY1113305T1 (el)
DK (1) DK1858864T3 (el)
ES (1) ES2388744T3 (el)
HK (1) HK1119675A1 (el)
HU (1) HUS1700033I1 (el)
LT (1) LTC1858864I2 (el)
LU (1) LUC00033I2 (el)
NZ (3) NZ599001A (el)
PL (1) PL1858864T3 (el)
PT (1) PT1858864E (el)
SI (1) SI1858864T1 (el)
WO (1) WO2006099385A2 (el)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110039943A1 (en) * 2005-03-14 2011-02-17 Robert Alonso Methods for treating skin disorders with topical nitrogen mustard compositions
US8501818B2 (en) * 2005-03-14 2013-08-06 Ceptaris Therapeutics, Inc. Stabilized compositions of alkylating agents and methods of using same
US7872050B2 (en) * 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
NZ613219A (en) 2008-01-04 2014-11-28 Intellikine Llc Heterocyclic containing entities, compositions and methods
US8193182B2 (en) * 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
SI3494960T1 (sl) * 2008-03-27 2021-04-30 Helsinn Healthcare Sa Stabilizirani sestavki alkilirajočih sredstev in metode uporabe le-teh
CN102164579B (zh) * 2008-09-25 2014-10-15 赛福伦公司 苯达莫司汀的液体配制品
WO2010036380A1 (en) 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors
EP2427195B1 (en) 2009-05-07 2019-05-01 Intellikine, LLC Heterocyclic compounds and uses thereof
US8545892B2 (en) * 2009-06-26 2013-10-01 Nano Pharmaceutical Laboratories, Llc Sustained release beads and suspensions including the same for sustained delivery of active ingredients
PT3158991T (pt) 2010-01-28 2021-06-23 Eagle Pharmaceuticals Inc Formulações de bendamustina
EP2542058B1 (en) 2010-03-02 2018-10-10 RXi Pharmaceuticals Corporation Effective sensitizing dose of a gelled immunomodulating topical composition
ES2593256T3 (es) 2010-05-21 2016-12-07 Infinity Pharmaceuticals, Inc. Compuestos químicos, composiciones y métodos para las modulaciones de cinasas
CA2817577A1 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
UA115767C2 (uk) 2011-01-10 2017-12-26 Інфініті Фармасьютікалз, Інк. Способи отримання ізохінолінонів і тверді форми ізохінолінонів
WO2013009800A2 (en) * 2011-07-11 2013-01-17 Ceptaris Therapeutics, Inc. Compositions of alkylating agents and methods of treating skin disorders therewith
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8969363B2 (en) 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PE20141371A1 (es) 2011-08-29 2014-10-13 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US20140005148A1 (en) * 2012-06-29 2014-01-02 Coldstream Laboratories Inc. Stable liquid formulations of nitrogen mustards
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
KR20160061911A (ko) 2013-04-08 2016-06-01 데니스 엠. 브라운 최적하 투여된 화학 화합물의 치료 효과
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EA201690713A1 (ru) 2013-10-04 2016-08-31 Инфинити Фармасьютикалз, Инк. Гетероциклические соединения и их применения
DK3119397T3 (da) 2014-03-19 2022-03-28 Infinity Pharmaceuticals Inc Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
RU2016147362A (ru) 2014-05-09 2018-06-13 ОРОМЕДИКС ФАРМА ЭлЭлСи Препараты жидкого концетрата циклофосфамида
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
JP6921759B2 (ja) 2015-06-04 2021-08-18 クリティテック・インコーポレイテッド 捕集装置および使用法
AU2016322552B2 (en) 2015-09-14 2021-03-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
RU2737934C2 (ru) 2016-04-04 2020-12-07 Крититек, Инк. Способы лечения солидных опухолей
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR20190033526A (ko) 2016-06-24 2019-03-29 인피니티 파마슈티칼스, 인코포레이티드 병용 요법
SG11201909840TA (en) 2017-06-09 2019-11-28 Crititech Inc Treatment of epithelial cysts by intracystic injection of antineoplastic particles
AU2018284247B2 (en) 2017-06-14 2020-04-30 Crititech Inc. Methods for treating lung disorders
RU2020110399A (ru) 2017-10-03 2021-11-09 Крититек, Инк. Местная доставка противоопухолевых частиц в комбинации с системной доставкой иммунотерапевтических агентов для лечения рака
JP6584588B2 (ja) * 2017-12-22 2019-10-02 レオキシン・エルエルシー セルライトの治療のための組成物及び方法
US20190365698A1 (en) * 2018-05-31 2019-12-05 Crititech, Inc. Use of Antineoplastic Agents to Stimulate the Immune System for Treatment of Cancer
WO2023059148A1 (ko) 2021-10-08 2023-04-13 기초과학연구원 항암 치료 개선을 위한 2-클로로-n,n-디에틸에틸아민 염산염의 용도

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US312290A (en) * 1885-02-17 James g
US157545A (en) * 1874-12-08 Improvement in car-couplings
US79492A (en) * 1868-06-30 Improvement in weae-plates foe, boots and shoes
US4083692A (en) * 1970-06-04 1978-04-11 The United States Of America As Represented By The Secretary Of The Army Detection and estimation of microquantities of alkylating agents
US3767792A (en) * 1971-07-02 1973-10-23 Stanley Drug Products Inc Method for controlling the toxicity of drug products
US3904766A (en) * 1973-06-19 1975-09-09 Scott Eugene J Van Treatment of psoriasis
US4206222A (en) * 1977-06-23 1980-06-03 Societe Civile Particuliere De Brevets Suffren Method for preparing a substance having properties against collagen diseases and products obtained
WO1987004154A1 (en) 1986-01-03 1987-07-16 The University Of Melbourne Melphalan derivatives
US4863910A (en) * 1986-05-20 1989-09-05 Takeo Takayanagi Complexes of AZO compounds and/or their salts and an antitumor agent and a method for reducing the growth of tumors
US4725438A (en) * 1986-05-29 1988-02-16 Leazer Billie S Aloe vera ointment
IE60588B1 (en) * 1986-07-30 1994-07-27 Sumitomo Pharma Carbapenem compound in crystalline form, and its production and use
US5326790A (en) * 1986-11-19 1994-07-05 Dermatologic Research Corporation Administration of skin medications by use of dicarboxylic acids and derivatives
US4853388A (en) * 1987-05-15 1989-08-01 Pearlman Dale L Method for treating psoriasis with cytotoxic agents
US5051363A (en) * 1987-06-26 1991-09-24 University Of Pennsylvania Method for modifying the toxicity of DNA reactive cross-linking agents to cells
US5229422A (en) * 1987-09-07 1993-07-20 Teijin Limited Extemporaneous preparation type kit of a pharmaceutical substance-containing fat emulsion
GB8727157D0 (en) 1987-11-19 1987-12-23 Wellcome Found Pharmaceutical formulations
US5098717A (en) 1987-12-09 1992-03-24 Thames Pharmacal Co., Inc. Method of treatment for pruritus
US4888354A (en) * 1987-12-21 1989-12-19 Theratech, Inc. Skin penetration enhancement using free base and acid addition salt combinations of active agents
US5719197A (en) * 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
DE4005911C1 (el) * 1990-02-24 1991-04-25 Gmn Georg Mueller Nuernberg Ag, 8500 Nuernberg, De
US4949641A (en) * 1990-03-05 1990-08-21 The United States Of America As Represented By The Secretary Of The Army Method of safely detoxifying mustard gases
US6764681B2 (en) * 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US5820872A (en) * 1992-11-18 1998-10-13 Yale University Methods and compositions for improving the effectiveness of X-irradiation therapy for the treatment of an internal solid tumor
EP0716589A4 (en) * 1993-07-23 1997-06-11 Morris Herstein COSMETIC COMPOSITION STIMULATING THE RENEWAL OF THE SKIN WITH A PROLONGED IRRITATION ELIMINATION EFFECT
FR2728166A1 (fr) * 1994-12-19 1996-06-21 Oreal Composition topique contenant un antagoniste de substance p
GB9501052D0 (en) * 1995-01-19 1995-03-08 Cancer Res Campaign Tech Improvements relating to prodrugs
US6551611B2 (en) 1995-09-28 2003-04-22 Schering Aktiengesellschaft Hormone replacement therapy method
US5744460A (en) 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US6124108A (en) * 1996-05-15 2000-09-26 The United States Of America As Represented By The Secretary Of The Army Protein biomarker for mustard chemical injury
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
ATE326238T1 (de) * 1996-06-27 2006-06-15 Chugai Pharmaceutical Co Ltd Mittel gegen myelome, welches zusammen mit antitumorwirkstoffen auf der basis von stickstoff-senfgasen verwendet werden kann
EP1024833A1 (en) * 1996-07-11 2000-08-09 Farmarc Nederland B.V. Pharmaceutical composition containing acid addition salt of basic drug
US6753155B1 (en) * 1997-05-13 2004-06-22 The United States Of America As Represented By The Secretary Of The Army Protein biomarker for mustard chemical injury
EP1019034A2 (en) 1997-07-01 2000-07-19 Atherogenics, Inc. Antioxidant enhancement of therapy for hyperproliferative conditions
AU760252B2 (en) 1998-01-30 2003-05-08 Cold Spring Harbor Laboratory Modulation of cell proliferation, methods and reagents
GB9805868D0 (en) * 1998-03-20 1998-05-13 Zeneca Ltd Anti-tumour agents
US20060079492A1 (en) 1999-10-25 2006-04-13 Ahlem Clarence N Compositions and treatment methods
US6329148B1 (en) * 1999-02-16 2001-12-11 The Board Of Trustees Of The Leland Stanford University Combined therapy of diterpenoid triepoxides and death domain receptor ligands for synergistic killing of tumor cells
US6017902A (en) * 1999-02-25 2000-01-25 Brookhaven Science Associates Boron containing amino acid compounds and methods for their use
US6395721B1 (en) 2000-01-05 2002-05-28 Leonard Bloom Low potency unpreserved sterile topical corticosteroid compositions for dermatitis
US20020146692A1 (en) * 2000-01-21 2002-10-10 Victoria Yamazaki Methods and materials relating to G protein-coupled receptor-like polypeptides and polynucleotides
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US20030215471A1 (en) 2001-01-31 2003-11-20 Wilmott James M. Surfactant free topical compositions and method for rapid preparation thereof
US7547673B2 (en) * 2001-09-13 2009-06-16 The Johns Hopkins University Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production
WO2003094954A1 (en) * 2001-09-25 2003-11-20 Quick Med Technologies, Inc. Composition and method for minimizing or avoiding adverse effects of vesicants
US20030082229A1 (en) 2001-11-01 2003-05-01 Board Of Regents, The University Of Texas Systems Parenteral chlorambucil for treatment of malignant and autoimmune disease and methods of use
US6885492B2 (en) * 2001-11-08 2005-04-26 Imaginative Optics, Inc. Spatial light modulator apparatus
CA2504665C (en) 2002-11-12 2012-12-18 Jewish General Hospital Combination of a nitrogen mustard analogue and imatinib for the treatment of chronic lymphocytic leukemia
MXPA05005161A (es) 2002-11-18 2005-07-22 Celgene Corp Metodos de utilizacion y composiciones que comprenden (-)3- (3, 4-dimetoxi- fenil)-3 -(1-oxo -1, 3-dihidro- isoindol- 2-il)- propionamida.
US8088605B2 (en) 2002-12-04 2012-01-03 Technologies Biolactics Inc. Exopolysaccharides delivery system for active molecules
US20050039228A1 (en) * 2003-06-19 2005-02-17 The Samuel Roberts Noble Foundation Methods and compositions for analysis of plant gene function
WO2005007129A2 (en) 2003-07-17 2005-01-27 Angiotech International Ag Topical formulations with bioactive components
US20070287719A1 (en) * 2005-03-11 2007-12-13 Pfizer Inc Salts, Prodrugs and Formulations of 1-[5-(4-Amino-7-Isopropyl-7H-Pyrrolo[2,3-D]Pyrimidine-5-Carbonyl)-2-Methoxy-Phenyl]-3-(2,4-Dichloro-Phenyl)-Urea
US8501818B2 (en) * 2005-03-14 2013-08-06 Ceptaris Therapeutics, Inc. Stabilized compositions of alkylating agents and methods of using same
US7872050B2 (en) 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
US20120157545A1 (en) 2005-03-14 2012-06-21 Robert Alonso Methods for treating skin disorders with topical nitrogen mustard compositions
US20110039943A1 (en) 2005-03-14 2011-02-17 Robert Alonso Methods for treating skin disorders with topical nitrogen mustard compositions
US20060281720A1 (en) * 2005-06-08 2006-12-14 Loria Roger M 5-Androstenediol As An Inhibitor of Gliomas
SI3494960T1 (sl) * 2008-03-27 2021-04-30 Helsinn Healthcare Sa Stabilizirani sestavki alkilirajočih sredstev in metode uporabe le-teh
WO2013009800A2 (en) 2011-07-11 2013-01-17 Ceptaris Therapeutics, Inc. Compositions of alkylating agents and methods of treating skin disorders therewith

Also Published As

Publication number Publication date
JP2008533152A (ja) 2008-08-21
WO2006099385A8 (en) 2008-03-13
JP5671514B2 (ja) 2015-02-18
CY1113305T1 (el) 2016-04-13
PL1858864T3 (pl) 2012-11-30
EP1858864B1 (en) 2012-07-04
PT1858864E (pt) 2012-09-25
KR20070120163A (ko) 2007-12-21
KR101168252B1 (ko) 2012-07-30
WO2006099385A3 (en) 2007-04-19
US20080194699A1 (en) 2008-08-14
LUC00033I2 (el) 2017-10-11
HK1119675A1 (en) 2009-03-13
CN101175735B (zh) 2014-04-23
US20140155491A1 (en) 2014-06-05
CY2017027I2 (el) 2018-04-04
US8501819B2 (en) 2013-08-06
HUS1700033I1 (hu) 2017-09-28
AU2006223076A1 (en) 2006-09-21
US20100041767A1 (en) 2010-02-18
US8450375B2 (en) 2013-05-28
US20130310461A1 (en) 2013-11-21
LUC00033I1 (el) 2017-08-10
NZ561268A (en) 2010-12-24
EP1858864A2 (en) 2007-11-28
JP5236457B2 (ja) 2013-07-17
AU2006223076B2 (en) 2012-02-09
US20140194526A1 (en) 2014-07-10
JP2013091643A (ja) 2013-05-16
US20060205694A1 (en) 2006-09-14
LTPA2017026I1 (lt) 2017-09-11
US20110065803A1 (en) 2011-03-17
ES2388744T3 (es) 2012-10-18
SI1858864T1 (sl) 2012-10-30
CN101175735A (zh) 2008-05-07
CA2600468C (en) 2015-05-05
CA2600468A1 (en) 2006-09-21
US8664278B2 (en) 2014-03-04
NZ589188A (en) 2012-06-29
NZ599001A (en) 2013-03-28
DK1858864T3 (da) 2012-09-10
US7838564B2 (en) 2010-11-23
LTC1858864I2 (lt) 2018-06-25
US7872050B2 (en) 2011-01-18
WO2006099385A2 (en) 2006-09-21
EP1858864A4 (en) 2008-04-30
US9382191B2 (en) 2016-07-05

Similar Documents

Publication Publication Date Title
CY2017027I1 (el) Σταθεροποιημενες συνθεσεις πτητικων αλκυλιωτικων παραγοντων και μεθοδοι χρησης αυτων
CY2019010I1 (el) Νεες ενωσεις και συνθεσεις και μεθοδοι χρησης
CY2017006I1 (el) Αερολυμενες φθοροκινολονες και χρησεις αυτων
CY2017040I2 (el) Συνθεσεις και μεθοδοι για διαμορφωση ματισματος smn2
CY2019039I1 (el) Συνθεσεις προκαρυωτικης αμμωνiακης λυασης φαινυλαλανινης και μεθοδοι χρησιμοποιησης αυτων των συνθεσεων
CY2015043I2 (el) Ενωσεις και συνθεσεις ως αναστολεις των πρωτεϊνικων κινασων
DE602005017635D1 (de) Harzzusammensetzung und formteil daraus
CY2014026I2 (el) Συνθεσεις και χρησεις για θεραπεια σκληρυνσης κατα πλακας
ITMI20050262A1 (it) Sostanze composizioni e metodi di trattamento dell'alopecia
BRPI0716354A2 (pt) "composiÇço e mÉtodo"
DE502005009598D1 (de) Partikelstabilisierte emulsionen
DK1812025T3 (da) Stabiliserede bakteriofagformuleringer
ATE546047T1 (de) Synergistische mischungen aus anthranilamid- invertebrat-pestbekämpfungsmitteln
CY2019042I1 (el) Οφθαλμολογικες συνθεσεις και η χρηση τους
DE602005013968D1 (de) Polyorganosiloxan und härtbare zusammensetzung daraus
DE602006005208D1 (de) Tonerzusammensetzung und Verfahren
DE602005016978D1 (de) Quecksilberfreisetzende Zusammensetzungen
DE602006016137D1 (de) Harzzusammensetzungen und harzformkörper
DE602006000877D1 (de) Emulsionszusammensetzung
DE602006011271D1 (de) Anthelminthische zusammensetzung
FR2885520B1 (fr) Composition cosmetique
FR2885521B1 (fr) Composition cosmetique
DE602004000946D1 (de) Dimethylpolysiloxan -Zusammensetzung
DE602007001998D1 (de) Tonerzusammensetzungen und Verfahren
ITMI20051658A1 (it) Composizioni cosmetiche